About Zinc finger protein 492
Zinc finger protein 492 (ZNF492) is a protein
from Homo sapiens identified by UniProt accession
Q9P255, 531 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Zinc finger protein 492 |
| UniProt accession | Q9P255 |
| Gene | ZNF492 |
| Organism | Homo sapiens |
| Length | 531 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- upper extremity fracture · score 0.06
- Down syndrome · score 0.04
- hepatocellular carcinoma · score 0.01
- sclerosing cholangitis · score 0.00
- uterine leiomyosarcoma · score 0.00
- type 2 diabetes mellitus · score 0.00
- neoplasm · score 0.00
- nonpapillary renal cell carcinoma · score 0.00
- chronic hepatitis B virus infection · score 0.00
- breast angiosarcoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P255-F1 | alphafold | PREDICTED | 72.99 | — |
Amino-acid sequence (531 residues)
MLENYRNLVF VGIAASKPDL ITCLEQGKEP WNVKRHEMVA EPPVVCSYFA RDLWPKQGKK NYFQKVILRR YKKCGCENLQ LRKYCKSMDE CKVHKECYNG LNQCLTTTQN KIFQCDKYVK VFHKFSNSNR HTIRHTGKKS FKCKECEKSF CMLSHLAQHK RIHSGEKPYK CKECGKAYNE TSNLSTHKRI HTGKKPYKCE ECGKAFNRLS HLTTHKIIHT GKKPYKCEEC GKAFNQSANL TTHKRIHTGE KPYKCEECGR AFSQSSTLTA HKIIHAGEKP YKCEECGKAF SQSSTLTTHK IIHTGEKFYK CEECGKAFSQ LSHLTTHKRI HSGEKPYKCE ECGKAFKQSS TLTTHKRIHA GEKFYKCEVC SKAFSRFSHL TTHKRIHTGE KPYKCEECGK AFNLSSQLTT HKIIHTGEKP YKCEECGKAF NQSSTLSKHK VIHTGEKPYK YEECGKAFNQ SSHLTTHKMI HTGEKPYKCE ECGKAFNNSS ILNRHKMIHT GEKLYKPESC NNACDNIAKI SKYKRNCAGE K
Explore Zinc finger protein 492 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets